Frontlight ResearchEarly access
CompletedNo phase
Clareon PanOptix Pro vs. Clareon PanOptix - Study A
Key facts
- Who runs it
- Alcon Research
- Where
- Bloomfield Hills, Cincinnati, Houston, Kansas City, Mt. Pleasant, Nashville, Salt Lake City, and Torrance, United StatesSee the 8 sites
- Trial code
- Status
- Completed
- People taking part
- 87 people enrolled
- Started
- 18 Jun 2024
- Ended
- 30 Apr 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CPO Pro IOL
- CPO IOL
- Cataract surgery
- Record updated
- 12 December 2025
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Understand and sign an ethics committee-approved informed consent form
- Willing and able to attend all scheduled study visits as required by the protocol
- Planned cataract surgery (both eyes)
- Preoperative corneal astigmatism less that 1.00 diopter in each eye
- Other protocol-defined inclusion criteria may apply
Who cannot take part
- Ocular conditions as specified in the protocol
- Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding
- Subjects who desire monovision correction
- Other protocol-defined exclusion criteria may apply
Where in United States
- Grosinger, Spigelman & Grey Eye Surgeons, P.C.Bloomfield Hills, United States
- Cincinnati Eye InstituteCincinnati, United States
- Houston Eye AssociatesHouston, United States
- Moyes Eye CenterKansas City, United States
- Carolina Eyecare Physicians LLCMt. Pleasant, United States
- Vision for LifeNashville, United States
- The Eye Institute of UtahSalt Lake City, United States
- Wolstan & Goldberg Eye AssociatesTorrance, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
The 2 groups in the trial
- CPO Pro IOLTreatment being tested
CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
Treatment: CPO Pro IOL, CPO IOL, and Cataract surgery
- CPO IOLExisting treatment, for comparison
CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
Treatment: CPO Pro IOL, CPO IOL, and Cataract surgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Contralateral Study of Clareon PanOptix Pro vs. Clareon PanOptix
- Record updated
- 12 December 2025